Compare Stocks

2 / 10
Try these comparisons:

Stock Comparison

LQDA vs INVA

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
LQDA
Liquidia Corporation

Biotechnology

HealthcareNASDAQ • US
Market Cap$3.66B
5Y Perf.+356.1%
INVA
Innoviva, Inc.

Biotechnology

HealthcareNASDAQ • US
Market Cap$1.91B
5Y Perf.+61.2%

LQDA vs INVA — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
LQDA logoLQDA
INVA logoINVA
IndustryBiotechnologyBiotechnology
Market Cap$3.66B$1.91B
Revenue (TTM)$69M$424M
Net Income (TTM)$-122M$504M
Gross Margin89.4%76.2%
Operating Margin-155.0%14.8%
Forward P/E17.5x11.8x
Total Debt$122M$269M
Cash & Equiv.$176M$551M

LQDA vs INVALong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

LQDA
INVA
StockMay 20May 26Return
Liquidia Corporation (LQDA)100456.1+356.1%
Innoviva, Inc. (INVA)100161.2+61.2%

Price return only. Dividends and distributions are not included.

Quick Verdict: LQDA vs INVA

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: INVA leads in 5 of 7 categories, making it the strongest pick for growth and revenue expansion and valuation and capital efficiency. Liquidia Corporation is the stronger pick specifically for recent price momentum and sentiment. As sector peers, any of these can serve as alternatives in the same allocation.
LQDA
Liquidia Corporation
The Long-Run Compounder

LQDA is the clearest fit if your priority is long-term compounding.

  • 279.6% 10Y total return vs INVA's 90.5%
  • +171.2% vs INVA's +20.4%
Best for: long-term compounding
INVA
Innoviva, Inc.
The Income Pick

INVA carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.

  • Dividend streak 0 yrs, beta 0.13
  • Rev growth 18.5%, EPS growth 8.2%, 3Y rev CAGR 8.7%
  • Lower volatility, beta 0.13, Low D/E 22.9%, current ratio 14.64x
Best for: income & stability and growth exposure
See the full category breakdown
CategoryWinnerWhy
GrowthINVA logoINVA18.5% revenue growth vs LQDA's -20.0%
ValueINVA logoINVALower P/E (11.8x vs 17.5x)
Quality / MarginsINVA logoINVA118.9% margin vs LQDA's -176.0%
Stability / SafetyINVA logoINVABeta 0.13 vs LQDA's 1.24, lower leverage
DividendsTieNeither stock pays a meaningful dividend
Momentum (1Y)LQDA logoLQDA+171.2% vs INVA's +20.4%
Efficiency (ROA)INVA logoINVA32.4% ROA vs LQDA's -44.2%, ROIC 14.2% vs -5.0%

LQDA vs INVA — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

LQDALiquidia Corporation
FY 2020
Promotion Agreement
100.0%$739,628
Research and Development Services
0.0%$0
INVAInnoviva, Inc.
FY 2025
Royalty
57.5%$236M
Product
41.8%$172M
License And Other Revenue
0.7%$3M

LQDA vs INVA — Financial Metrics

Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLINVALAGGINGLQDA

Income & Cash Flow (Last 12 Months)

INVA leads this category, winning 4 of 6 comparable metrics.

INVA is the larger business by revenue, generating $424M annually — 6.1x LQDA's $69M. INVA is the more profitable business, keeping 118.9% of every revenue dollar as net income compared to LQDA's -176.0%.

MetricLQDA logoLQDALiquidia Corporat…INVA logoINVAInnoviva, Inc.
RevenueTrailing 12 months$69M$424M
EBITDAEarnings before interest/tax-$106M$86M
Net IncomeAfter-tax profit-$122M$504M
Free Cash FlowCash after capex-$108M$181M
Gross MarginGross profit ÷ Revenue+89.4%+76.2%
Operating MarginEBIT ÷ Revenue-155.0%+14.8%
Net MarginNet income ÷ Revenue-176.0%+118.9%
FCF MarginFCF ÷ Revenue-155.8%+42.8%
Rev. Growth (YoY)Latest quarter vs prior year+11.2%+10.6%
EPS Growth (YoY)Latest quarter vs prior year+86.4%+4.0%
INVA leads this category, winning 4 of 6 comparable metrics.

Valuation Metrics

INVA leads this category, winning 3 of 4 comparable metrics.
MetricLQDA logoLQDALiquidia Corporat…INVA logoINVAInnoviva, Inc.
Market CapShares × price$3.7B$1.9B
Enterprise ValueMkt cap + debt − cash$3.6B$1.6B
Trailing P/EPrice ÷ TTM EPS-25.39x6.82x
Forward P/EPrice ÷ next-FY EPS est.17.48x11.77x
PEG RatioP/E ÷ EPS growth rate0.66x
EV / EBITDAEnterprise value multiple7.99x
Price / SalesMarket cap ÷ Revenue261.40x4.49x
Price / BookPrice ÷ Book value/share42.92x1.63x
Price / FCFMarket cap ÷ FCF9.76x
INVA leads this category, winning 3 of 4 comparable metrics.

Profitability & Efficiency

INVA leads this category, winning 8 of 9 comparable metrics.

INVA delivers a 46.5% return on equity — every $100 of shareholder capital generates $46 in annual profit, vs $-6 for LQDA. INVA carries lower financial leverage with a 0.23x debt-to-equity ratio, signaling a more conservative balance sheet compared to LQDA's 1.58x. On the Piotroski fundamental quality scale (0–9), INVA scores 5/9 vs LQDA's 1/9, reflecting solid financial health.

MetricLQDA logoLQDALiquidia Corporat…INVA logoINVAInnoviva, Inc.
ROE (TTM)Return on equity-5.5%+46.5%
ROA (TTM)Return on assets-44.2%+32.4%
ROICReturn on invested capital-5.0%+14.2%
ROCEReturn on capital employed-84.1%+12.4%
Piotroski ScoreFundamental quality 0–915
Debt / EquityFinancial leverage1.58x0.23x
Net DebtTotal debt minus cash-$54M-$282M
Cash & Equiv.Liquid assets$176M$551M
Total DebtShort + long-term debt$122M$269M
Interest CoverageEBIT ÷ Interest expense-4.63x57.62x
INVA leads this category, winning 8 of 9 comparable metrics.

Total Returns (Dividends Reinvested)

LQDA leads this category, winning 6 of 6 comparable metrics.

A $10,000 investment in LQDA five years ago would be worth $165,255 today (with dividends reinvested), compared to $19,549 for INVA. Over the past 12 months, LQDA leads with a +171.2% total return vs INVA's +20.4%. The 3-year compound annual growth rate (CAGR) favors LQDA at 77.0% vs INVA's 24.5% — a key indicator of consistent wealth creation.

MetricLQDA logoLQDALiquidia Corporat…INVA logoINVAInnoviva, Inc.
YTD ReturnYear-to-date+34.2%+13.3%
1-Year ReturnPast 12 months+171.2%+20.4%
3-Year ReturnCumulative with dividends+454.5%+92.8%
5-Year ReturnCumulative with dividends+1552.5%+95.5%
10-Year ReturnCumulative with dividends+279.6%+90.5%
CAGR (3Y)Annualised 3-year return+77.0%+24.5%
LQDA leads this category, winning 6 of 6 comparable metrics.

Risk & Volatility

Evenly matched — LQDA and INVA each lead in 1 of 2 comparable metrics.

INVA is the less volatile stock with a 0.13 beta — it tends to amplify market swings less than LQDA's 1.24 beta. A beta below 1.0 means the stock typically moves less than the S&P 500.

MetricLQDA logoLQDALiquidia Corporat…INVA logoINVAInnoviva, Inc.
Beta (5Y)Sensitivity to S&P 5001.24x0.13x
52-Week HighHighest price in past year$46.67$25.15
52-Week LowLowest price in past year$11.85$16.52
% of 52W HighCurrent price vs 52-week peak+90.3%+89.5%
RSI (14)Momentum oscillator 0–10059.241.5
Avg Volume (50D)Average daily shares traded1.2M615K
Evenly matched — LQDA and INVA each lead in 1 of 2 comparable metrics.

Analyst Outlook

Insufficient data to determine a leader in this category.

Wall Street rates LQDA as "Buy" and INVA as "Buy". Consensus price targets imply 67.3% upside for INVA (target: $38) vs 20.2% for LQDA (target: $51).

MetricLQDA logoLQDALiquidia Corporat…INVA logoINVAInnoviva, Inc.
Analyst RatingConsensus buy/hold/sellBuyBuy
Price TargetConsensus 12-month target$50.67$37.67
# AnalystsCovering analysts710
Dividend YieldAnnual dividend ÷ price
Dividend StreakConsecutive years of raises0
Dividend / ShareAnnual DPS
Buyback YieldShare repurchases ÷ mkt cap0.0%+0.2%
Insufficient data to determine a leader in this category.
Key Takeaway

INVA leads in 3 of 6 categories (Income & Cash Flow, Valuation Metrics). LQDA leads in 1 (Total Returns). 1 tied.

Best OverallInnoviva, Inc. (INVA)Leads 3 of 6 categories
Loading custom metrics...

LQDA vs INVA: Frequently Asked Questions

10 questions · data-driven answers · updated daily

01

Is LQDA or INVA a better buy right now?

For growth investors, Innoviva, Inc.

(INVA) is the stronger pick with 18. 5% revenue growth year-over-year, versus -20. 0% for Liquidia Corporation (LQDA). Innoviva, Inc. (INVA) offers the better valuation at 6. 8x trailing P/E (11. 8x forward), making it the more compelling value choice. Analysts rate Liquidia Corporation (LQDA) a "Buy" — based on 7 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which has the better valuation — LQDA or INVA?

On forward P/E, Innoviva, Inc.

is actually cheaper at 11. 8x.

03

Which is the better long-term investment — LQDA or INVA?

Over the past 5 years, Liquidia Corporation (LQDA) delivered a total return of +1553%, compared to +95.

5% for Innoviva, Inc. (INVA). Over 10 years, the gap is even starker: LQDA returned +279. 6% versus INVA's +90. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

04

Which is safer — LQDA or INVA?

By beta (market sensitivity over 5 years), Innoviva, Inc.

(INVA) is the lower-risk stock at 0. 13β versus Liquidia Corporation's 1. 24β — meaning LQDA is approximately 881% more volatile than INVA relative to the S&P 500. On balance sheet safety, Innoviva, Inc. (INVA) carries a lower debt/equity ratio of 23% versus 158% for Liquidia Corporation — giving it more financial flexibility in a downturn.

05

Which is growing faster — LQDA or INVA?

By revenue growth (latest reported year), Innoviva, Inc.

(INVA) is pulling ahead at 18. 5% versus -20. 0% for Liquidia Corporation (LQDA). On earnings-per-share growth, the picture is similar: Innoviva, Inc. grew EPS 816. 7% year-over-year, compared to -37. 2% for Liquidia Corporation. Over a 3-year CAGR, INVA leads at 8. 7% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

06

Which has better profit margins — LQDA or INVA?

Innoviva, Inc.

(INVA) is the more profitable company, earning 63. 8% net margin versus -931. 7% for Liquidia Corporation — meaning it keeps 63. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: INVA leads at 38. 5% versus -866. 6% for LQDA. At the gross margin level — before operating expenses — INVA leads at 72. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

07

Is LQDA or INVA more undervalued right now?

On forward earnings alone, Innoviva, Inc.

(INVA) trades at 11. 8x forward P/E versus 17. 5x for Liquidia Corporation — 5. 7x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for INVA: 67. 3% to $37. 67.

08

Which pays a better dividend — LQDA or INVA?

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

09

Is LQDA or INVA better for a retirement portfolio?

For long-horizon retirement investors, Innoviva, Inc.

(INVA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 13)). Both have compounded well over 10 years (INVA: +90. 5%, LQDA: +279. 6%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

10

What are the main differences between LQDA and INVA?

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: LQDA is a small-cap quality compounder stock; INVA is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.

Stocks Like

LQDA

High-Growth Disruptor

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 560%
  • Gross Margin > 53%
Run This Screen
Stocks Like

INVA

Quality Mega-Cap Compounder

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 5%
  • Net Margin > 71%
Run This Screen
Custom Screen

Beat Both

Find stocks that outperform LQDA and INVA on the metrics below

Revenue Growth>
%
(LQDA: 1121.7% · INVA: 10.6%)

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.